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Objectives: Transilluminated powered phlebectomy (TriVex) is a new surgical technique that uses tumescent dissection,
transillumination, and powered phlebectomy. The purpose of this study was to compare TriVex with conventional
varicose vein surgery in terms of pain, cosmesis, recurrence, complications, and operating time.
Methods: One hundred eighty-eight limbs in 141 patients (33 men, 108 women; mean age, 42.5 years) with varicose veins
were randomised to conventional (n 100) or TriVex (n 88). Exclusion criteria were venous ulceration or deep venous
disease. Varicosities were graded with CEAP and clinical assessment (grades 1-3), and were similar in both groups.
Randomization was single blinded. Long or short saphenous vein ligation or stripping was performed as indicated with
duplex scanning. Operative time was from skin incision to leg bandaging. Phlebectomy was performed with conventional
stab avulsions or TriVex. Patients completed assessment forms preoperatively and postoperatively (2, 6, 26, 52 weeks),
and this was supplemented with physician clinical evaluation. Pain was assessed with visual analog score.
Results: There was a significant difference in the number of incisions for phlebectomy in the two groups (conventional, n
 29; TriVex, n  5; P < .0001). TriVex was faster in the grade 3 (extensive) group, but this did not reach statistical
significance. There was no difference in mean postoperative pain score over 8 days in the two groups (P  .4624). At 2
weeks there was no significant difference between the groups with regard to bruising (P  .77), cellulitis (P  .33), and
numbness (P  .33). At 6 weeks there was no significant difference between the groups with regard to nerve injury (P 
.97), residual veins (P  .79), cosmetic score (P  .837), and overall satisfaction (P  .878). At 6 and 12 months, there
was no significant difference in cosmesis (P .955, P .088, respectively) or recurrence (P .27, P .11, respectively).
Conclusions: TriVex is a safe and effective method for excision of varicosities and compares well, after a learning curve,
with conventional surgery in regard to complications and recurrence. It has the advantage of a trend toward reduced
operating time in extensive varicosities, and significantly fewer incisions, although there was no perceived difference in
cosmesis during follow-up. (J Vasc Surg 2004;39:88-94.)
Treatment of varicose veins constitutes a major part of
the workload of a vascular surgeon.1 Although there are
various treatment methods, surgery remains the standard
therapy for symptomatic varicose veins.2 In 1996 Dr Rob-
ert Muller described the technique of removing varicosities
by using small skin stab incisions and hook phlebectomy.3,4
Although this technique has achieved worldwide usage and
has yielded satisfactory results, it can be tedious to perform,
and this can lead to missed varices, which, along with
multiple incisions, can impair cosmetic results.
Transilluminated powered phlebectomy (TriVex) is a
new surgical technique that combines endoscopic powered
vein resection and ablation of superficial varicosities with
tumescent anaesthesia and irrigated illumination.5 The per-
ceived advantages of this new technique are direct visual-
ization of the vein to be avulsed and the removal of veins
through only a few incisions, resulting in better cosmesis
and minimizing the risk for missed veins. We prospectively
compared TriVex with conventional varicose vein surgery,
with reference to operative time, postoperative pain, com-
plications, cosmesis, and recurrence.
MATERIALS AND METHOD
Approval for the study was obtained from the Feder-
ated Dublin Voluntary Hospitals Joint Research Ethics
Committee. Patients awaiting varicose vein surgery were
sent an appointment time for a triage clinic and an infor-
mation package containing detailed descriptions of conven-
tional phlebectomy and TriVex. This information was sup-
plemented at the triage clinic with direct interview, and
patients were encouraged to discuss the diagnosis and
surgical procedure. On the day of surgery consent was
obtained from the patient, who had been fully informed of
both procedures, and randomization to one or the other
procedure was accomplished with a random number gen-
erator. Patients were not aware of which procedure they
had undergone, although clever patients would know by
looking at their legs once the bandages were removed.
Patients were blinded from the treatment method through-
out the study period.
All patients underwent venous duplex scanning, and
reflux was defined as reverse flow for greater than 0.5
seconds. Disease was graded with the CEAP classification;
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all patients had either class 2 or class 3 disease. There was no
significant differences in distribution between the groups:
class 2, conventional treatment, 61%, versus Trivex, 53.4%,
and class 3, conventional treatment, 39%, versus Trivex,
46.6%. In addition, local classification (grades 1-3) was also
used. This is an arbitrary classification based on severity of
veins and projected operating time (Table I), and has been
beneficial in previous waiting list initiatives at our hospital.6
The exclusion criteria were deep venous insufficiency on
duplex scan, active or healed venous ulceration, and recur-
rent varicose veins. The indications for surgery are illus-
trated in Table II.
All varicosities were marked preoperatively with an
indelible marker. Stab incisions for conventional surgery
are placed every 3 to 4 cm along the length of the varicos-
ities for complete excision. This formed the basis of the
incision count at the end of procedure. A record was made
of the actual number of incisions made and the estimated
number of incisions for the alternative procedure, whether
TriVex or conventional surgery.
Surgical technique. Patients received prophylactic
low molecular weight heparin (Clexane, 20 mg) preopera-
tively, and a single intravenous dose of antibiotic (Augmen-
tin plus Co-Amoxiclav, 1.2 g) at induction. This is the
standard protocol for all varicose vein surgery carried out at
our institution. All of our patients are operated on as
inpatients, and tend not to mobilize immediately. No pa-
tient had deep venous thrombosis, justifying our practice of
routine prophylaxis. Antibiotic prophylaxis is the institu-
tion norm even for clean surgery, and this may explain why
our incidence of wound infection is so low. All procedures
were performed with the patient under general anesthesia.
The saphenofemoral junction was approached through a
standard 4-cm incision above the groin crease. The junc-
tion was clearly identified, and all tributaries were clipped
and divided with a disposable clip applicator. The long
saphenous vein and its duplication, if present, were stripped
to the level of the knee with a disposable vein stripper. In
patients requiring saphenopopliteal junction ligation the
junction was marked preoperatively at duplex scanning. A
transverse skin incision was made with the patient in the
prone position, and the junction was clearly identified and
ligated. In all patients the groin and popliteal incisions were
infiltrated with 0.25% bupivacaine at the end of the
procedure.
Thigh and calf varicosities were treated as per random-
ization. Conventional stab avulsions were performed
through 2-mm incisions with an ophthalmic scalpel. Varady
hooks were used to remove varices, which were then
avulsed with a mosquito-toothed micro Halstead forceps
(Aesculap, BH 119R).
TriVex was performed through 3-mm incisions with
the protocol of Spitz et al.5 The TriVex system consists of a
combined irrigation-illumination wand (TCI; Smith &
Nephew Endoscopy Division, Andover, Mass), a powered
vein resector, a 300-W xenon light source, and a pressure
infusion system. The illuminator has a bevelled tip set at 45
degrees, and is bi-channelled. One channel connects to the
xenon light source, and the other connects to a pressure
infusion system set at 700 mm Hg. The tumescent solution
comprises 400 mg of lignocaine and 2 mL of 1:1000
adrenaline added to a liter of 0.9% saline solution. The
powered resector has an inner rotary blade and a stationary
sheath with a lateral window. The speed is set between 800
and 1000 rpm, and the device can function in three modes:
forward, reverse, or oscillating. It also has two channels,
one for infusing 0.9% saline solution under gravity, and the
other connected to a conventional suction apparatus.
At the first stage of tumescence the illuminator is passed
in the subcutaneous plane deep to and along the varicosities
at the same time as infusion of the tumescent solution. This
causes hydrodissection of the veins and increases the field of
visualization. The resector is then passed through a similar
incision placed in the same axis parallel to the illuminator.
Both instruments work in unison; the illuminator is placed
deeper to the resector, displaying the vein as a silhouette.
The lateral window of the resector engages the vein with




Aches and pains 28 31
Bleeding 1 0




Unsightly veins 30 23




n % n %
1 Varicosities below knee (operation time 1 hr) 16 16 19 21.6
2 Varicosities below and above knee, not extensive or below knee
alone and extensive (operation time 1–2 hr)
60 60 47 53.4
3 Varicosities below and above knee and extensive (operation time 2 hr) 24 24 22 25
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suction, which is then morcellated and removed with the
irrigation-suction system. Excision of the vein is completed
with slow retraction of the handset along the line of the
vein. Incisions for TriVex were strategically placed to re-
move maximal vein clusters within the arc of the instrumen-
tation.
After resection of the varicosities, second-stage tumes-
cent anaesthesia was instilled until the appearance of peau
d’orange.5 This minimized ecchymosis and hematoma for-
mation. Groin and popliteal wounds were closed with deep
and subcuticular sutures. Stab wounds were closed with
steristrips. Crepe bandages were applied at the end of the
procedure, and were replaced with thigh-length class I
compression stockings at discharge.
A standardized leaflet containing detailed postopera-
tive instructions was given to each patient. In addition,
patients were advised to contact the department in case of
complications.
Clinical data collection. Data collection was per-
formed by completion of a series of simple questionnaires
prepared to reflect the patients’ objective and subjective
symptoms, and these were supplemented with clinical ex-
amination by a physician. All patient responses were simpli-
fied by the use of a 10-point visual analog scoring system at
2 and 6 weeks, and 6 and 12 months postoperatively.
Preoperative and follow-up data were entered into a data-
base using Microsoft Access (Redmond, Wash).
Operative time was recorded from the time of groin or
popliteal fossa incision to completion of application of
bandages. When both the saphenofemoral and saphenopo-
pliteal junctions were operated on, the time for surgery was
the total time taken, including time for turning the patient.
Overall time included setup time for TriVex instrumenta-
tion.
Statistical analysis. Appropriate statistical tests were
used to compare the TriVex and conventional groups for
the outcome variables. For highly skewed continuous data,
such as pain scores, nonparametric tests (Mann-Whitney)
were carried out. In the case of other quantitative data,
analysis of variance or t tests were used. 2 and Fisher exact
tests were used to compare the two groups in the case of
count data. A power analysis was also conducted for the
three major outcome variables, that is, duration of surgery,
cosmetic score, and pain score at weeks 2 and 6. In each
case a two-sided test with a significance level of 5% was
used. The results indicated a power of 99% for the cosmetic
score and pain scores at weeks 2 and 6 to detect a difference
of 2 on the 10-point visual scale. The results for the
duration of surgery suggested a power of 84% to detect a
difference of 10 minutes.
RESULTS
During the study 201 patients were assessed for vari-
cose vein surgery. Sixty patients were excluded from the
study because of recurrent veins (n  21), chronic venous
insufficiency (n  14), or refusal to participate (n  25).
One hundred eighty-eight procedures were performed in
141 patients (47 bilateral). There were 33 men and 108
women, with mean age of 42.5 years (range, 20-68 years).
Saphenofemoral junction ligation and stripping of long
saphenous vein was performed in 150 (79.9%) limbs (con-
ventional, 82, vs TriVex, 68), and saphenopopliteal junc-
tion ligation and short saphenous vein avulsion in 14 (7.4%)
limbs (conventional, 5, vs TriVex, 9). In an additional 14
(7.4%) limbs ligation of both the saphenofemoral and saphe-
nopopliteal junctions was performed, in conjunction with
long saphenous vein stripping and short saphenous vein avul-
sion (conventional, 8, vs TriVex, 6). Ten (5.3%) limbs under-
went phlebectomy alone (conventional, 5, vs TriVex, 5). One
hundred operations were performed in the conventional
group, and 88 in the TriVex group. All limbs had either CEAP
class 2 or 3 disease, with similar distribution in both groups.
Table I illustrates the distribution of veins based on the local St
James’s Hospital classification. There was no significant differ-
ence between groups.
The mean number of actual incisions made for the
conventional method was 29 1.28 (range, 6-70), and the
mean estimated number of incisions if TriVex had been
used was 4  0.15 (range, 2-8). The mean actual number
of incisions for TriVex was 5  0.17 (range, 2-8), and the
estimated number if conventional surgery had been used
was 28  1.37 (range, 6-80). The number of incisions
made in the TriVex group was significantly fewer (P 
.0001).
Table III shows the operating time (in minutes) for
each clinical grade in both groups. TriVex was approxi-
mately 18 minutes faster in treatment of grade 3 varicosi-
ties, although this did not reach statistical significance (P
.16).
The mean pain score was calculated from the visual
analog pain scores at the end of postoperative weeks 1, 2,
and 6. A score of zero signified “no pain,” and a score of 10
signified the “worst possible pain.” The mean pain scores
are illustrated in Fig 1; there was no statistical difference
between both groups. All patients were sent home with a
standard prescription for analgesia (Celebrex, 200 mg once
daily, and distalgesic, two tablets three times a day, for 1
week). We were unable to collect data on medication
consumed, because patient compliance was poor.
Table IV illustrates complications, including cellulitis,
cutaneous nerve injury, residual veins, and severe bruising,
at 2 and 6 weeks postoperatively. At 2 weeks postopera-
tively, cellulitis was noted in three (3.00%) patients after










Conventional 1 15 120 54.00
2 15 150 63.55
3 50 160 84.70*
TriVex 1 10 110 52.00
2 15 120 66.08
3 40 130 67.08*
*P  .16.
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conventional treatment, compared with two (2.3%) pa-
tients after TriVex (P  .33). These settled quickly with
antibiotics, and no further treatment was required. Cuta-
neous nerve injury was defined as numbness and paresthe-
sia, and occurred at 2 weeks in 25% and 18% of patients,
respectively, who underwent conventional treatment or
TriVex, and at 6 weeks in 19% and 16% of patients, respec-
tively, after conventional or TriVex. At 1 year there was one
residual cutaneous nerve injury in each group (3%). There
were no major nerve injuries in either group.
At 2 weeks, residual veins were noted in three patients
in the conventional group and six patients in the TriVex
group. At 6 weeks this increased to eight patients in each
group. Severe bruising occurred in 7.0% and 9.1% at 2
weeks postoperatively for the conventional and TriVex
groups, respectively, and by 6 weeks postoperatively there
was none in either group. No groin wound hematoma was
recorded in either group, and there was no deep vein
thrombosis. However, one patient had a calf hematoma,
and required readmission. Statistically, there was no differ-
ence between the groups with regard to cellulitis, cutane-
ous nerve injury, severe bruising, or residual veins.
The cosmetic score was recorded at 6, 26, and 52
weeks. On the visual analog scale zero represents “worst
possible result” imaginable, and 10 represents “best possi-
ble” cosmetic result. The number of limbs followed up after
conventional surgery was 69 at 26 weeks and 34 at 52
weeks, compared with 57 limbs at 26 weeks and 37 at 52
weeks after TriVex. The mean cosmetic score for the con-
ventional group was 8.27 0.35, and for TriVex was 7.44
 0.38. There was no significant difference between the
groups (Fig 2).
At 26 weeks there were six recurrences (of 69 limbs
reviewed) in the conventional group, and six recurrences
(of 57 limbs) in the TriVex group. At 52 weeks there were
two recurrences (of 34 limbs reviewed) in the conventional
group, and seven recurrences (of 37 limbs reviewed) in the
TriVex group. All veins in the same initial area and also new






n % n %
Cellulitis 2 3 3.0 2 2.3 .33
6 0 0 0 0
Cutaneous nerve injury 2 25 25.0 16 18.1 .33
6 19 19.0 14 15.9 .97
52 1 2.9 1 2.7 .99
Residual veins 2 3 3.0 6 6.8
6 8 8.0 8 9.1 .79
Severe Bruising 2 7 7.0 8 9.1 .77
6 0 0 0 0
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sources were classified as recurrences. There was only one
recurrence at 52 weeks in the TriVex group if the first 20
cases were excluded from analysis, and two in the conven-
tional group. All recurrences were in limbs with grade 3
disease, and there was no statistical significant difference
between the groups.
Overall satisfaction for surgery, which was defined as a
score of 8 or greater on the visual analog score, where zero
represents “very dissatisfied” and 10 represents “very satis-
fied,” was 91% and 87% at 6 weeks postoperatively for
conventional and TriVex surgery, respectively. There was
no statistical difference (P  .878) between groups. When
asked “Would you recommend this operation to a friend?,”
86.8% and 89.1% said “yes” and 13.2% and 10.9% said “no”
for conventional and TriVex, respectively.
DISCUSSION
Several reports have confirmed the efficacy and safety of
TriVex5,7-10; however, this study is the first published
prospective comparative randomized trial comparing con-
ventional varicose vein surgery with the new technique of
powered phlebectomy (TriVex). Both groups were similar
in terms of demographic data and extent of varices.
The number of incisions used in our TriVex group was
similar to that reported by Spitz et al,5 who first reported the
use of this powered phlebectomy device. The number of
incisions in our conventional group was greater than in their
historical control group (28 vs 17). Spitz and colleagues had
an incision ratio of approximately 3:1, and found a signifi-
cantly better cosmetic result in their TriVex group. In con-
trast, we had an incision ratio of 7:1, and would have expected
a better cosmetic result with TriVex. However, this was not
the case; cosmesis was similar in both groups.
Our study did not show any difference in operating
time for grades 1 and 2 varicosities, but the mean operating
time was faster by approximately 18 minutes in grade 3
varicosities in the TriVex group, although this did not reach
statistical significance. This is in contrast to the findings of
Spitz et al,5 who reported a mean operating time of 41
minutes for TriVex and 75 minutes for their control sub-
jects, a difference of 34 minutes. This difference may be
explained in that the operating time in our study included
the set-up time for the TriVex instrumentation, and fur-
thermore, the practice at our institution of having two
surgeons working on a patient simultaneously. TriVex was
faster by approximately 18 minutes in patients with exten-
sive varicosities, and we are now looking at possible differ-
ences with single-surgeon surgery.
Assessment of pain scores showed no difference be-
tween groups. This supports the findings of others.5,7-10 It
is our policy to infiltrate groin and popliteal incisions with
bupivacaine at the end of the procedure. Patients recorded
their pain scores without differentiating pain from saphe-
nofemoral junction or saphenopopliteal junction dissection
sites, and no attempt was made to segregate these variables,
because the entire procedure was assessed.
Cutaneous nerve injury associated with numbness and
paresthesia occurred in 15.9% of TriVex limbs at 6 weeks,
which is less than reported by Cheshire et al.9 However, our
reported incidence of cutaneous nerve injury of 19% in the
conventional group is higher than in reported series.11-13
At 1 year the incidence was significantly reduced, suggest-
ing that most of these were neuropraxia. Permanent dam-
age to cutaneous nerves was similar in both groups, and
there were no major nerve injuries.
A high incidence of hematoma was reported in many
series; Scavee et al10 reported an incidence of 45% in their
TriVex group and 25% after conventional phlebectomy.
Their incidence of calf hematoma was 25% and 2.5% for
TriVex and conventional surgery, respectively, but it is not
clear how hematoma was defined. It is our opinion that our
incidence of severe calf hematoma was low because of the
introduction of a high-pressure infusion system for both
primary and secondary tumescence. We reported severe
bruising in 9.1% of the TriVex group and 7.0% of the
conventional group at 2 weeks, but this had completely
Fig 2. Cosmetic scores.
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resolved by 6 weeks in all patients. Our incidence of cellu-
litis was similar to that reported by Cheshire et al9 in their
TriVex group, and we found no difference in either group
of our patients.
There was a higher number of recurrences in the TriVex
group (21.2%; 7 of 33) compared with the conventional
group (6.2%; 2 of 32) at 52 weeks postoperatively. However,
six of these recurrences were in the first 20 TriVex procedures,
which represents our early experience with the technique. We
suggest that a longer familiarization period with the technique
is necessary to obtain results superior to those of conventional
surgery. Data analysis was begun after a learning curve that
included 20 patients, and in hindsight this was insufficient to
learn this new technique.
CONCLUSION
This study shows that TriVex is a safe and effective
method for excision of varicosities. When performed by
trained surgeons it has a comparable complication rate with
that of conventional surgery. It has the advantage of a trend
toward reduced operating time in extensive varicosities,
and results in significantly fewer incisions, although there
was no perceived difference in cosmesis during interval
follow-up. The disposables used for the TriVex procedure
amount to EUR 262 per patient ($314). Despite the
additional cost, we believe that TriVex has a definite place
in treating varicose veins. when time and manpower are
issues.
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DISCUSSION
Dr Peter R. Bell (Leicester, England). I don’t think you really
proved the last statement that you made, where you said powered
phlebectomy was better than the conventional technique. There
was no data to prove that.
Just a few questions. Who did the operations, experienced
surgeons or juniors? Was the study blinded? Did you blind the
assessors who decided on the cosmesis?
All this fluid you gave them, how many attacks of cardiac
failure did you have?
What do you mean by neurapraxia? It’s a huge incidence of
neurapraxia. Where did it occur?
And you forgot one important element, the cost.
Dr Prakash Madhavan. I think we were very clear in the
paper to say that, although there was a trend that TriVex was faster
in patients with extensive varicosities, it did not reach statistical
significance. In addition, in the Conclusion, all we have claimed is
that there appears to be an advantage in using TriVex, especially in
patients with extensive varicosities.
All patients are operated on by an experienced group of senior
registrars and trainees with consultant supervision.
The patients were blinded to the treatment groups. They did
not know what procedure they had undergone until the bandages
were taken off.
There was no incidence of cardiac failure in the TriVex group.
With regard to neurapraxia, this was assessed by asking them a
simple question: “Do you have any tingling or numbness in your
leg?” The figures quoted are in the distribution of the saphenous
and sural nerves. The apparently high incidence of nerve injury at
first follow-up reduced to 3% at 1 year without any major nerve
injuries.
Dr Robert B. McLafferty (Springfield, Ill). I was hoping that
TriVex was going to show better results. I continually struggle
with feeling the pressure to learn all these new technologies pre-
sented in our specialty, and now I realize I don’t need to go out
and learn something new. You have shown that conventional
treatment is as good as TriVex.
A mean of 29 incisions for varicose veins seems awfully high
for the conventional method. I wonder if there was bias in your
study, knowing you were comparing TriVex with conventional
treatment. I don’t think I’d make that many incisions even in a leg
with extensive varicose veins.
Dr Madhavan. Well, this was based on standard techniques
that we use for conventional surgery. We actually validated this
by looking at the number of incisions we used in patients before
the trial. This would be the average number of incisions we
would use for extensive varicose veins. This was based on a
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